Potent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 1, 2012, Pages 51-55

  Izumi, Kazuki ^a   Watanabe, Kentaro ^b   Oishi, Shinya ^b   Fujii, Nobutaka ^b   Matsuoka, Masao ^a   Sarafanos, Stefan G ^c   Kodama, Eiichi N ^a,d  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c University of Missouri   (United States)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENFUVIRTIDE; GALACTOSIDASE; GLYCOPROTEIN GP 41; N TERMINAL HEPTAD REPEAT DERIVED PEPTIDE N36; N TERMINAL HEPTAD REPEAT DERIVED PEPTIDE N36 T; N TERMINAL HEPTAD REPEAT DERIVED PEPTIDE N43 T; N TERMINAL HEPTAD REPEAT DERIVED PEPTIDE N45 T; N TERMINAL HEPTAD REPEAT DERIVED PEPTIDE N46; N TERMINAL HEPTAD REPEAT DERIVED PEPTIDE N54; TRYPTOPHAN; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEPTIDE; PEPTIDE FRAGMENT;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; BINDING SITE; CELL LINE; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BINDING SITES; CELL LINE; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES;

EID: 84856393554     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1836     Document Type: Article

References (33)

1. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70:777-810.
2. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998; 95:15613-15617.
3. Malashkevich VN, Chan DC, Chutkowski CT, Kim PS. Crystal structure of the simian immunodefciency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci USA 1998; 95:9134-9139.
4. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
5. Epand RF, Sayer BG, Epand RM. The tryptophan-rich region of HIV gp41 and the promotion of cholesterol-rich domains. Biochemistry 2005; 44:5525-5531.
6. Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999; 73:2469-2480.
7. Schibli DJ, Montelaro RC, Vogel HJ. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 2001; 40:9570-9578.
8. Vishwanathan SA, Hunter E. Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J Virol 2008; 82:5118-5126.
9. Peisajovich SG, Gallo SA, Blumenthal R, Shai Y. C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem 2003; 278:21012-21017.
10. Oishi S, Ito S, Nishikawa H, et al. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J Med Chem 2008; 51:388-391.
11. Nishikawa H, Kodama E, Sakakibara A, et al. Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. Antiviral Res 2008; 80:71-76.
12. Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005; 280:11259-11273.
13. Champagne K, Shishido A, Root MJ. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem 2009; 284:3619-3627.
14. Kliger Y, Gallo SA, Peisajovich SG, et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 2001; 276:1391-1397.
15. Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58:714-722.
16. Baldwin CE, Sanders RW, Deng Y, et al. Emergence of a drug-dependent human immunodefciency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004; 78:12428-12437.
17. Cabrera C, Marfl S, Garcia E, et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006; 20:2075-2080.
18. Fikkert V, Cherepanov P, Van Laethem K, et al. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother 2002; 46:3954-3962.
19. Izumi K, Kodama E, Shimura K, et al. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J Biol Chem 2009; 284:4914-4920.
20. Lohrengel S, Hermann F, Hagmann I, et al. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005; 79:10237-10246.
21. Mink M, Mosier SM, Janumpalli S, et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005; 79:12447-12454.
22. Oliveira AC, Martins AN, Pires AF, et al. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART. AIDS Res Hum Retroviruses 2009; 25:193-198.
23. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
24. Nishikawa H, Nakamura S, Kodama E, et al. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol 2009; 41:891-899.
25. Chackerian B, Long EM, Luciw PA, Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 1997; 71:3932-3939.
26. Izumi K, Nakamura S, Nakano H, et al. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Res 2010; 87:179-186.
27. Naito T, Izumi K, Kodama E, et al. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother 2009; 53:1013-1018.
28. Nameki D, Kodama E, Ikeuchi M, et al. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 2005; 79:764-770.
29. Shimura K, Nameki D, Kajiwara K, et al. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem 2010; 285:39471-39480.
30. Watabe T, Terakawa Y, Watanabe K, et al. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution. J Mol Biol 2009; 392:657-665.
31. Otaka A, Nakamura M, Nameki D, et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl 2002; 41:2937-2940.
32. Bianchi E, Finotto M, Ingallinella P, et al. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 2005; 102:12903-12908.
33. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348:2228-2238.